Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: We sought to validate the prognostic utility of comprehensive genomic profiling (CGP)-based molecular stratification for patients with endometrial carcinoma and to assess co-occurring biomarkers across subtypes.
Methods: This study included patients from a de-identified nationwide (US-based) endometrial cancer clinicogenomic database who underwent CGP testing as part of routine care. Molecular subtypes were classified as POLE mutated (POLEmut), MSI-H, TP53 mutated (TP53mut), and no specific molecular profile (NSMP). Time to next treatment and overall survival were compared between molecular subtypes, with multivariable Cox models adjusted for relevant covariables.
Results: Of 1,139 evaluated patients with advanced or recurrent endometrial carcinoma, the prevalence of the 4 molecular subtypes was 1% POLEmut, 22% high microsatellite instability, 47% TP53mut, and 31% NSMP. Compared with NSMP patients, POLEmut patients had numerically more favorable time to next treatment (HR 0.50, 95% CI 0.21 to 1.21) and overall survival (HR 0.52, 95% CI 0.17 to 1.66). High microsatellite instability patients had similar time to next treatment (HR 1.08, 95% CI 0.89 to 1.30) and overall survival (HR 0.91, 95% CI 0.71 to 1.19) relative to NSMP patients. TP53mut patients had the least favorable outcomes for time to next treatment (compared with NSMP, HR 1.39, 95% CI 1.19 to 1.62) and overall survival (HR 2.15, 95% CI 1.77 to 2.61). In multivariable analysis, TP53mut status was associated with less favorable time to next treatment and overall survival. Frequencies of other biomarkers varied by molecular subtype.
Conclusions: The Cancer Genome Atlas (TCGA)/Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular classifier for endometrial carcinoma can be recapitulated using CGP and provides prognostic stratification even within an advanced or recurrent disease cohort. CGP for molecular subclassification could support trial design and enrollment and inform treatment escalation or selection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijgc.2025.102107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Cost-Effectiveness Between Digital Health Interventions and Pharmacotherapy for Depression: Systematic Review.
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
Participants' Perspectives on the iCareBreast Mobile-Based Perioperative Care Program for Women Undergoing Breast Cancer Surgery: Qualitative Process Evaluation.
JMIR Hum Factors
September 2025
KK Women's and Children's Hospital, Singapore, Singapore.
Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.
View Article and Find Full Text PDFElectrochemical Sensors for Rapid Cardiovascular Disease Diagnostics.
ACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFEvaluation of ambulatory use of daratumumab hyaluronidase injection.
J Oncol Pharm Pract
September 2025
Hematology/Oncology, Scripps Clinic, La Jolla, USA.
IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.
View Article and Find Full Text PDFNeural alpha oscillations and auditory steady-state responses during adaptation to a cochlear implant.
Cereb Cortex
August 2025
Department of Psychology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.
The human auditory system must distinguish relevant sounds from noise. Severe hearing loss can be treated with cochlear implants (CIs), but how the brain adapts to electrical hearing remains unclear. This study examined adaptation to unilateral CI use in the first and seventh months after CI activation using speech comprehension measures and electroencephalography recordings, both during passive listening and an active spatial listening task.
View Article and Find Full Text PDF